BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27523078)

  • 1. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis.
    Kozaki K; IInuma M; Takagi T; Fukuda T; Sanpei T; Terunuma Y; Yatabe Y; Akano K
    Ther Apher Dial; 2016 Aug; 20(4):376-82. PubMed ID: 27523078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
    Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
    In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Maeda S; Yabuuchi J; Nobuta H; Makiishi T; Hirose K
    Ther Apher Dial; 2015 Aug; 19(4):342-8. PubMed ID: 26386222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites.
    Ito T; Hanafusa N; Soneda N; Isoai A; Kobayashi R; Torii N; Kato M
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3224-3232. PubMed ID: 34250635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
    Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
    Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites.
    Ito T; Hanafusa N; Fukui M; Yamamoto H; Watanabe Y; Noiri E; Iwase S; Miyagawa K; Fujita T; Nangaku M
    Ther Apher Dial; 2014 Feb; 18(1):87-92. PubMed ID: 24499089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cell-Free Ascites Reinfusion Therapy(CART)Modified by Keisuke Matsusaki(KM-CART)at Our Hospital].
    Iwaki R; Shindo K; Kawahara H; Nanba N; Kuramoto Y; Beppu T; Uesugi T; Tanaka Y; Uesugi Y
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2165-2167. PubMed ID: 30692319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of Major Problems in the Cell-Free and Concentrated Ascites Reinfusion Therapy System─Constructing of Cell-Free and Concentrated Ascites Reinfusion Therapy System Using External Pressure for Filtration.
    Yoshizawa M; Nakatsuji Y
    Ther Apher Dial; 2019 Jun; 23(3):233-236. PubMed ID: 31033153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
    Hanafusa N; Isoai A; Ishihara T; Inoue T; Ishitani K; Utsugisawa T; Yamaka T; Ito T; Sugiyama H; Arakawa A; Yamada Y; Itano Y; Onodera H; Kobayashi R; Torii N; Numata T; Kashiwabara T; Matsuno Y; Kato M
    PLoS One; 2017; 12(5):e0177303. PubMed ID: 28510606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.
    Namisaki T; Tsuji Y; Kitade M; Yorioka N; Fujinaga Y; Sawada Y; Nishimura N; Kitagawa K; Inoue T; Takaya H; Kaji K; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
    In Vivo; 2022; 36(3):1477-1484. PubMed ID: 35478114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel automatic ascites filtration and concentration equipment with multi-ring-type roller pump units for cell-free and concentrated ascites reinfusion therapy.
    Okahisa T; Sogabe M; Nakagawa T; Tanaka K; Tomonari T; Taniguchi T; Takahashi A; Kinouchi Y; Nishioka J; Igata N; Yanagawa H; Komatsu T; Ohnishi Y; Fukuhara M; Ishikawa M; Shibata H; Shinomiya H; Nakasono M; Kishi F; Komai K; Tatsuki Y; Murashima T; Deguchi Y; Aramaki H; Fukumitsu H; Takayama T
    Artif Organs; 2020 Aug; 44(8):856-872. PubMed ID: 32187379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrated ascites reinfusion therapy for sinusoidal obstructive syndrome after hematopoietic stem cell transplantation.
    Takahashi H; Sakai R; Fujita A; Kuwabara H; Hattori Y; Matsuura S; Ohshima R; Hagihara M; Tomita N; Ishigatsubo Y; Fujisawa S
    Artif Organs; 2013 Oct; 37(10):932-6. PubMed ID: 23692354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technical Performance and Clinical Effectiveness of Drop Type With Adjustable Concentrator-Cell Free and Concentrated Ascites Reinfusion Therapy.
    Yamada Y; Harada M; Yamaguchi A; Kobayashi Y; Chino T; Minowa T; Kosuge T; Tsukada W; Hashimoto K; Kamijo Y
    Artif Organs; 2017 Dec; 41(12):1135-1144. PubMed ID: 28589706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
    Tsubokura M; Adegawa Y; Kojima M; Tanosaki R; Ohtake R; Kase Y; Iwashita N; Kasane M; Nakabayashi S; Takeuchi S; Kato K; Boku N; Kanemitsu Y; Okusaka T; Fujimoto H; Yonemori K; Ishiki H; Kawamura K; Satomi E; Matsushita H
    BMC Cancer; 2022 Mar; 22(1):268. PubMed ID: 35287609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.
    Maeda O; Ando T; Ishiguro K; Watanabe O; Miyahara R; Nakamura M; Funasaka K; Kazuhiro F; Ando Y; Goto H
    Mol Clin Oncol; 2014 Nov; 2(6):1103-1106. PubMed ID: 25279205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical evaluation of processed ascites in patients undergoing cell-free and concentrated ascites reinfusion therapy.
    Nakamura H; Hanafusa N; Kitamura K; Nakamura H; Sekihara H; Shimizu K; Anayama M; Makino Y; Tamura K; Nagasawa M
    Ther Apher Dial; 2020 Oct; 24(5):516-523. PubMed ID: 32524759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Refractory Ascites for Liver Transplant Candidates: A Novel Cell-free and Concentrated Ascites Reinfusion Therapy.
    Shimizu S; Ohira M; Nakano R; Imaoka Y; Sato K; Tahara H; Ide K; Kobayashi T; Kuroda S; Ono H; Tanaka Y; Ohdan H
    Transplant Proc; 2019 Oct; 51(8):2740-2744. PubMed ID: 31563243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites.
    Zaak D; Paquet KJ; Kuhn R
    Z Gastroenterol; 2001 Jan; 39(1):5-10. PubMed ID: 11215366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.
    Hanada R; Yokomichi N; Kato C; Miki K; Oyama S; Morita T; Kawahara R
    Support Care Cancer; 2018 May; 26(5):1489-1497. PubMed ID: 29168037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.